Consensus on the monitoring, treatment, and prevention of leukaemia relapse after allogeneic haematopoietic stem cell transplantation in China: 2024 update.

Saved in:
Bibliographic Details
Title: Consensus on the monitoring, treatment, and prevention of leukaemia relapse after allogeneic haematopoietic stem cell transplantation in China: 2024 update.
Authors: Wang Y; Peking University People's Hospital & Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, No. 11 Xizhimen South Street, Xicheng District, Beijing, 100044, PR China., Chang YJ; Peking University People's Hospital & Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, No. 11 Xizhimen South Street, Xicheng District, Beijing, 100044, PR China., Chen J; Shanghai Children's Medical Center, Shanghai, PR China., Han M; Chinese Academy of Medical Sciences and Peking Union Medical College, Institute of Hematology and Blood Disease Hospital, Tianjin, PR China., Hu J; The Second Affiliated Hospital of Fujian Medical University, Quanzhou, PR China., Hu J; Ruijin Hospital, Shanghai Jiao Tong University, Shanghai, PR China., Huang H; First Affiliated Hospital of Zhejiang University, Hangzhou, PR China., Lai Y; The First Affiliated Hospital of Guangxi Medical University, Nanning, PR China., Liu D; General Hospital of PLA(People's Liberation Army of China), Beijing, PR China., Liu Q; Nanfang Hospital of Southern Medical University, Guangzhou, PR China., Luo Y; First Affiliated Hospital of Zhejiang University, Hangzhou, PR China., Jiang EL; Chinese Academy of Medical Sciences and Peking Union Medical College, Institute of Hematology and Blood Disease Hospital, Tianjin, PR China., Jiang M; The First Affiliated Hospital of Xinjiang Medical University, Urumqi, PR China., Song Y; Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, PR China., Tang XW; The First Affiliated Hospital of Soochow University, Soochow, PR China., Wu D; The First Affiliated Hospital of Soochow University, Soochow, PR China., Xia LH; Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, PR China., Xu K; The First Affiliated Hospital of Xuzhou Medical University, Xuzhou, PR China., Zhang X; Xinqiao Hospital, Army Medical University, Chongqing, PR China., Zhang XH; Peking University People's Hospital & Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, No. 11 Xizhimen South Street, Xicheng District, Beijing, 100044, PR China., Huang X; Peking University People's Hospital & Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, No. 11 Xizhimen South Street, Xicheng District, Beijing, 100044, PR China; Peking-Tsinghua Center for Life Sciences, Beijing, PR China; State Key Laboratory of Natural and Biomimetic Drugs, Peking University, Beijing, PR China. Electronic address: xjhrm@medmail.com.cn.
Source: Cancer letters [Cancer Lett] 2024 Nov 28; Vol. 605, pp. 217264. Date of Electronic Publication: 2024 Sep 25.
Publication Type: Journal Article; Review; Consensus Statement
Journal Info: Publisher: Elsevier Science Ireland Country of Publication: Ireland NLM ID: 7600053 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1872-7980 (Electronic) Linking ISSN: 03043835 NLM ISO Abbreviation: Cancer Lett Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1872-7980
DOI:10.1016/j.canlet.2024.217264